Covid-19: NICE rejects five treatments over uncertain evidence and price in draft guidance - ISS-G20 Laboratorium Repository

NICE has recommended three drugs—nirmatrelvir plus ritonavir (Paxlovid), tocilizumab (RoActemra), and baricitinib (Olumiant)—for the treatment of covid-19 in adults, as part of draft guidance.

The review of the efficacy and cost effectiveness of drugs currently being used in the NHS to treat covid-19 considered treatments in the context of routine commissioning, rather than their use in exceptional circumstances, such as during a pandemic

Entire content available on: https://www.bmj.com/content/379/bmj.o2759